Horizon, Centauri Going to Avvinity And Beyond In New Immuno-Oncology JV

The UK gene-editing group Horizon Discovery and Centauri Therapeutics Ltd hope their newly formed immuno-oncology joint venture, called Avvinity Therapeutics, will create a proprietary platform able to discover novel immuno-oncology therapies for both solid tumors and leukaemias and give them access to a market currently worth £25bn and growing rapidly.